慢性肾脏病严重程度与EVAR术后30天再入院及一年死亡率的关系
本研究基于TrinetX多中心电子健康记录网络,回顾性纳入14,652例非破裂肾下腹主动脉瘤EVAR患者,按CKD分期分层并以非CKD为参照。倾向评分匹配后,CKD与更高的30天再入院率(27.3% vs 19.5%;OR 1.55,95%CI 1.40-1.72;P<0.001)、术后并发症及1年全因死亡率(14.2% vs 8.7%;HR 1.70,95%CI 1.48-1.95)相关,风险随CKD严重程度呈分级升高,以晚期(≥3b)疾病最为集中。
要点
- CKD患者EVAR术后30天再入院风险显著升高,匹配后OR为1.55。
- 再入院率随CKD分期呈分级升高,但非单调,2期出现早期峰值。
- 晚期CKD(≥3b)与1年死亡率独立相关,调整后HR为1.49。
核心结论
- CKD严重程度与EVAR术后30天再入院、术后并发症及1年死亡率呈分级、分期依赖的升高相关,最大且最一致的风险集中在晚期(≥3b)疾病而非某一离散阈值。
研究设计与样本
- 回顾性队列研究,使用TrinetX多中心联邦电子健康记录研究网络,纳入非破裂肾下EVAR患者14,652例,其中CKD患者5,418例。
- 主要比较为CKD与非CKD,采用人口学与合并症1:1倾向评分匹配,匹配后每组4,208例;另单独比较早期(<3b)与晚期(≥3b)CKD。
主要发现
- 匹配后CKD组30天再入院率为27.3%,非CKD组为19.5%(OR 1.55,95%CI 1.40-1.72;P<0.001)。
- 再入院率随CKD严重程度呈分级但非单调升高(Cochran-Armitage趋势检验P<0.001),最高见于4期、5期及终末期肾病。
- 2期再入院率(30.6%)高于3a期(23.6%)和3b期(25.8%),呈现早期非单调峰值。
- CKD组呼吸系统并发症(10.6% vs 5.6%)、卒中(2.6% vs 1.7%)和心肌梗死(3.5% vs 1.6%)均更高(所有P≤0.002)。
- CKD组1年全因死亡率更高(14.2% vs 8.7%;HR 1.70,95%CI 1.48-1.95),晚期CKD(≥3b)相对早期阶段的调整HR为1.49(95%CI 1.29-1.73)。
临床怎么用
- 对EVAR术前患者应进行精细CKD分期,以辅助围手术期风险分层和出院后随访计划。
- 晚期CKD(≥3b)患者术后早期再入院及1年死亡风险最高,需加强围手术期管理与出院后监测。
- 2期CKD患者再入院率出现早期峰值,提示早期CKD亦不可忽视术后随访。
局限性
- 本研究为回顾性队列研究,使用行政与电子健康记录数据,可能存在编码偏倚与未测量混杂。
- 原文未报告CKD分期的具体定义细节及不同CKD分期样本量,可能影响分期的精确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic kidney disease (CKD) is prevalent among patients undergoing endovascular aneurysm repair (EVAR) and is associated with increased cardiovascular and perioperative risk. Although the adverse impact of advanced CKD on long-term survival is well-documented, its association with early hospital utilization remains less clearly defined. This study evaluates the association between CKD stage and 30-day readmission following EVAR in a large, contemporary, multicenter cohort. METHODS: A retrospective cohort study was conducted using TrinetX, a multicenter, federated electronic health record research network. Patients undergoing nonruptured infrarenal EVAR were identified by current procedural terminology codes and stratified by CKD stage using international classification codes (ICD-10) diagnosis 1, with non-CKD patients as the reference cohort. The primary outcome was 30-day all-cause readmission; secondary outcomes were 30-day postoperative complications (respiratory complications, stroke, and myocardial infarction) and 1-year mortality. The primary comparison (CKD versus non-CKD) used 1:1 propensity score matching on demographics and comorbidities; a separate analysis compared early (<3b) and advanced (≥3b) CKD. RESULTS: A total of 14,652 patients undergoing nonruptured infrarenal EVAR were identified, of whom 5,418 had CKD. After matching (4,208 per arm), CKD was associated with higher 30-day readmission (27.3% vs 19.5%; odds ratio [OR] 1.55, 95% confidence interval [CI] 1.40-1.72; P < 0.001). Readmission rose across CKD severity in a graded but nonmonotonic pattern (Cochran-Armitage trend P < 0.001), with the highest rates in stage 4, stage 5, and end-stage renal disease. Notably, readmission in stage 2 (30.6%) exceeded that in both stage 3a (23.6%) and stage 3b (25.8%), an early-stage nonmonotonic peak. A day-2 sensitivity analysis showed the association was not an artifact of index-stay capture. CKD was also associated with higher respiratory complications (10.6% vs 5.6%), stroke (2.6% vs 1.7%), and myocardial infarction (3.5% vs 1.6%; all P ≤ 0.002). One-year all-cause mortality was higher among CKD patients (14.2% vs 8.7%; hazard ratio [HR] 1.70, 95% CI: 1.48-1.95), and advanced CKD (≥3b) was independently associated with mortality relative to earlier stages (adjusted HR: 1.49, 95% CI: 1.29-1.73). CONCLUSION: CKD severity is associated with a graded, stage-dependent increase in early readmission, postoperative complications, and 1-year mortality following EVAR, with the largest and most consistent risk concentrated in advanced (≥3b) disease rather than at a discrete threshold. Granular CKD staging may aid perioperative risk stratification and post discharge planning.
引用
- Moffat A, Ansingkar K, Rahimi M, et al. Chronic Kidney Disease Severity and 30-Day Hospital Readmission Following Endovascular Aneurysm Repair, with Secondary Assessment of One-Year Mortality. Ann Vasc Surg. 2026. PMID: 42617691. doi:10.1016/j.avsg.2026.08.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。